Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 14/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 8/20 | 0.32 |
| ▸ | CCR2 | P41597 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6722645 | 0.90 | PTGS2 (0.42) | PTGS2PTGS1 | |
| SCHEMBL6730523 | 0.90 | PTGS2 (0.42) | PTGS2PTGS1 | |
| SCHEMBL6722067 | 0.89 | CCR2 (0.36) | PIK3CDPIK3CAPIK3CBPIK3CGPTGS2 | |
| SCHEMBL6723555 | 0.89 | PIK3CD (0.37) | PIK3CDPIK3CAPIK3CBPIK3CGPTGS2 | |
| SCHEMBL6732458 | 0.88 | PIK3CD (0.34) | PIK3CDPIK3CAPIK3CBPIK3CGPTGS2 | |
| SCHEMBL6723090 | 0.88 | PTGS2 (0.37) | PTGS2PTGS1 | |
| SCHEMBL6726157 | 0.88 | PTGS2 (0.39) | PIK3CDPIK3CAPIK3CBPIK3CGPTGS2 | |
| SCHEMBL6723518 | 0.87 | PTGS2 (0.40) | PIK3CDPIK3CAPIK3CBPIK3CGPTGS2 | |
| SCHEMBL6721583 | 0.87 | PTGS2 (0.38) | PIK3CDPIK3CAPIK3CBPIK3CGPTGS2 | |
| SCHEMBL6726139 | 0.87 | PTGS2 (0.46) | PIK3CDPIK3CAPIK3CBPIK3CGPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092552-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
| US-20020183362-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2002-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183362-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | FPR2, FPR1, PTGES2 | PIK3CD 4290/4885PIK3CA 3770/4885PIK3CB 2965/4885 |
| US-20040092552-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | FPR2, PTGES2, FPR1 | PIK3CD 4382/4885PIK3CA 3934/4885PIK3CB 3178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.